

Development of a new personalized medical approach to treat B Cell lymphomas

ABOUT THE LECTURE

B cell lymphomas are hematological cancers that are rarely cured with current therapies, all of which have inherent toxicities and variable response rates. We recently found that the enzyme N-myristoyltransferase 2 (NMT2) is lost in a high proportion of human B cell lymphoma cell lines and tumors, and that this feature renders them highly sensitive to therapy with a new NMT inhibitor compound.

Speaker: **Prof Luc G Berthiaume**

*Prof of Cell Biology
University of Alberta, Canada*

Host: *Prof Patrick Casey*

*Senior Vice Dean of Research
Duke-NUS Graduate Medical School*

Date: Friday, 4 April 2014

Time: 11.00 — 12.00 PM

(Light refreshments will be served at 12:00 PM)

Venue: Duke-NUS Graduate Medical School
Amphitheatre, Level 2

Contact Person: Ms Cynthia Lim, Duke-NUS Research Affairs Department
Tel: 6601 2275 or Email: cynthia.lim@duke-nus.edu.sg


ABOUT THE SPEAKER

Luc Berthiaume is a Professor of Cell Biology at the University of Alberta, Alberta, Canada since 1995. His laboratory studies protein fatty acylation in cell signaling, apoptosis and cancer. Prof. Berthiaume received his Ph.D. in Biochemistry from University of Sherbrooke, Quebec, Canada studying the protein structure-function of enzymes with Dr. J. Sygusch. He then did post-doctoral fellowship with Dr. Marilyn Resh at the Memorial Sloan-Kettering Cancer Center in New York, where he began his studies on protein acylation and signaling.





SHUTTLE BUS ROUTE



LEGEND



TAXI TAXI STAND



CAR PARK



DROP-OFF POINT FOR A&E PATIENTS ONLY



SHUTTLE BUS



BUS STOP